米非司酮对子宫内膜厚度和血清性激素的影响  

The effect of mifepristone on human endometrium thickness and serum hormone levels

作　　者：陈玲玲[1] 邱晓燕[1] 陆贤伟[1] 吴梅珍[1] 

机构地区：[1]上海市第一人民医院妇产科,上海200080

出　　处：《徐州医学院学报》2001年第5期423-425,共3页Acta Academiae Medicinae Xuzhou

摘　　要：目的　根据长期口服米非司酮患者子宫内膜的阴道超声检查和性激素水平的测定 ,评价长期应用米非司酮的安全性。方法　采用自身对照 ,2 0例子宫肌瘤和子宫内膜异位症患者每天口服米非司酮 2 5mg共 3个月 ,在服药前卵泡期及服药后第 30天、6 0天和 90天行阴道超声检查 ,并同时采取静脉血备测性激素水平。结果　服药期间 2 0例对象全部停经 ,服药前后子宫内膜厚度有增加 ,但差别无显著性意义 (P >0 .0 5 )。在服药第 90天 ,13例子宫内膜厚度 <8mm和 7例子宫内膜厚度≥ 8mm ,最厚者为 17mm ,与雌二醇水平显著相关 (P <0 .0 1)。服药期间卵泡刺激素、黄体生成素及皮质醇水平无明显变化。结论　对长期口服米非司酮患者 ,应定期采用阴道超声检查子宫内膜形态 。Objectives To assess endometrium thickness by transvaginal ultrasonography and determine serum hormone levels in women with long-term receiving mifepristone. Furthermore, its safety was also explored. Methods A before-after study was used. Total 20 patients with myoma of uterus and endometriosis who received 25 mg of mifepristone daily prospectively for at least 3 months. Endovaginal ultrasonography was used for endometrial assessment on the day of follicle period before taking medicine and on the day 30, 60, 90 for follow-up visit, and blood samples were collected for sex hormone analysis. Results All of women taking this drug developed amenorrhea. The thickness of endometrium increased, but there was no significant difference from beginning to end. On the day 90 of receiving mifepristone, the endometrium thickness was<8 mm in 13 patients and≥8 mm in 7 patients. The thickness of endometrium was significantly associated with the level of E 2 in each case, and it was 17 mm at the most. There was no appreciable changes in the follicle stimulating hormone (FSH), luteinizing hormone LH or cortisol (C) levels in the blood samples before and during the treatment. Conclusions Transvaginal ultrasonography may be used termly to assess endometrial appearance in patients with long-term receiving mifepristone. The diagnostic uterine curettage should be applied based on the patient's clinical condition.

关 键 词：米非司酮 子宫内膜 阴道超声检查 性激素 

分 类 号：R977.12[医药卫生—药品] R969[医药卫生—药学]